Publications by authors named "Renee Poels"

Claim this Profile
S
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy.
Jort J van der Schans, Paresh Vishwasrao, Renée Poels, Morgan Antti, Ziyu Wang

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Afroditi Katsarou, Maria Sjöstrand, Jyoti Naik, Jorge Mansilla-Soto, Dionysia Kefala, Renée Poels

Sci Transl Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis.
Lisa C Holthof, Jort J van der Schans, Afroditi Katsarou, Renée Poels, Anne T Gelderloos

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.
Arwen Stikvoort, Jort van der Schans, Subhashis Sarkar, Renée Poels, Ruud Ruiter

Hemasphere· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.
Lisa C Holthof, Arwen Stikvoort, Hilma J van der Horst, Anne T Gelderloos, Renée Poels

Hemasphere· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
Renée Poels, Esther Drent, Roeland Lameris, Afroditi Katsarou, Maria Themeli

Int J Mol Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Esther Drent, Renée Poels, Ruud Ruiter, Niels W C J van de Donk, Sonja Zweegman

Clin Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Esther Drent, Renée Poels, Manon J Mulders, Niels W C J van de Donk, Maria Themeli

PLoS One· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Esther Drent, Maria Themeli, Renée Poels, Regina de Jong-Korlaar, Huipin Yuan

Mol Ther· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis